Market Research Logo

Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

Summary


Respiratory disorders, which affect components of the respiratory system such as the lungs and airway, are a broad range of chronic diseases with a variety of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate the muscles surrounding the bronchial tubes to relax and open the airways.

Recently approved products in COPD include multiple LABA/LAMA fixed-dose combinations, some of which are forecast to generate over $1 billion by 2023, and include GlaxoSmithKline (GSK)’s triple-combination therapy (fluticasone furoate plus umeclidinium bromide plus vilanterol trifenatate). The approval of novel biologics in the asthma market, including interleukin (IL)-targeting Nucala (mepolizumab), marketed by GSK, is also forecast to have a strong commercial impact on the market. Notable drivers of growth in the cystic fibrosis (CF) market are the recently approved disease-modifying therapies Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), both from Vertex.

Respiratory therapy area consists of indications that affect the lungs, bronchi, trachea, larynx, pharynx and nose in different ways, such as the scarring of lung tissue or the excessive production of mucus. Respiratory disease most commonly results in breathing difficulties, which can lead to disruptions in sleep, wheezing, anxiety and stress. In more severe cases shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders varies significantly across each indication and includes factors such as environment, occupation, genetic predisposition and aging.

In 2016, GSK was the leading company in terms of revenue generated from respiratory disorder products, accounting for 30.3% of the market, while Vertex had a small market share of 5.3%. However, the emergence of cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, which are considered disease-modifying therapies for CF, an indication which has traditionally only had symptomatic treatments, is set to have a substantial clinical and commercial impact. There are only two of these products on the market, Orkambi and Kalydeco, both of which were developed by Vertex.

The report “Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers” provides the following analysis -

  • Provides introduction to respiratory disorders, including disease epidemiology, symptoms, pathophysiology, co-morbidities and complications and prognosis. Methods of diagnosis are also provided. The chapter concludes with an analysis of the general treatment options.
  • Provides overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the respiratory disorders pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: leukemia, lymphoma and myeloma. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Presents forecast projections to 2023 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals, relating to respiratory disorder products. Some of the most prominent deals are discussed in detail.
Scope
  • Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%. What is driving this growth?
  • The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim. Which of these are forecast to experience the largest growth?
  • There have been many new approvals in the therapy area. Which drugs will achieve blockbuster status?
  • The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?
  • There are 930 respiratory products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
  • Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?
Reasons to buy
  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the respiratory pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at respiratory product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the respiratory deals landscape by analyzing trends in licensing and co-development deals.


  • GBI Research Report Guidance
  • Executive Summary
    • Strong Market Growth despite Key Patent Expirations
    • Majority of Pipeline Products Are in Early Stages of Development with Increasing Numbers of Biologics
    • Vertex Forecast to Become a Leading Player in Respiratory Disorder Market
  • Introduction
    • Therapy Area Introduction
    • Symptoms
    • Diagnosis
      • Asthma
      • Chronic Obstructive Pulmonary Disease
      • Idiopathic Pulmonary Fibrosis
      • Cystic Fibrosis
    • Etiology and Pathophysiology
      • Asthma
      • Chronic Obstructive Pulmonary Disease
      • Idiopathic Pulmonary Fibrosis
      • Cystic Fibrosis
    • Epidemiology
      • Table Respiratory Disorders Therapeutics Market, Global, Epidemiology, 2017
      • Asthma
        • Table Figure 1: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Asthma, 2016-2023
      • Chronic Obstructive Pulmonary Disease
        • Table Figure 2: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for COPD, 2016-2023
      • Idiopathic Pulmonary Fibrosis
        • Table Figure 3: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Idiopathic Pulmonary Fibrosis, 2016-2023
      • Cystic Fibrosis
        • Table Figure 4: Respiratory Disorders Therapeutics Market, Global, Epidemiology Patterns for Cystic Fibrosis, 2016-2023
    • Prognosis and Disease Staging
      • Asthma
        • Table Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 0-4 Years of Age
        • Table Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Children of 5-11 Years of Age
        • Table Respiratory Disorders Therapeutics Market, Global, Classification of Asthma Severity in Youths of 12 Years or More and Adults
      • Chronic Obstructive Pulmonary Disease
        • Table Respiratory Disorders Therapeutics Market, Global, COPD Disease Severity, 2016
        • Table Respiratory Disorders Therapeutics Market, Global, COPD Patient Risk Categories, 2016
      • Idiopathic Pulmonary Fibrosis
        • Table Respiratory Disorders Therapeutics Market, Global, IPF Severity Classification, 2016
        • Table Figure 5: Respiratory Disorders Therapeutics Market, Schematic Representation of Potential Clinical Courses of IPF
      • Cystic Fibrosis
        • Table Respiratory Disorders Therapeutics Market, Global, CF Severity Classification, 2016
        • Table Figure 6: Respiratory Disorders Therapeutics Market, Progression of CF
    • Treatment
      • Asthma
      • Chronic Obstructive Pulmonary Disease
        • Table Respiratory Disorders Therapeutics Market, Global, COPD Treatment Algorithm, 2016
      • Idiopathic Pulmonary Fibrosis
      • Cystic Fibrosis
        • Table Respiratory Disorders Therapeutics Market, Global, CF Treatment Plan, 2016
  • Key Marketed Products
    • Overview
      • Table Figure 7: Respiratory Disorders Therapeutics Market, Global, Key Marketed Products and Approved Indications, 2017
    • Advair - GSK
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Advair, 2017
      • Table Figure 8: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Advair ($bn), 2006-
      • Table Figure 9: Respiratory Disorders Therapeutics Market, Advair Market Share Within Asthma, Global, 2006-2023
    • Symbicort - AstraZeneca/Astellas
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Symbicort, 2017
      • Table Figure 10: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Symbicort ($bn), 2006-2023
      • Table Figure 11: Respiratory Disorders Therapeutics Market, Symbicort Market Share Within Asthma, Global, 2006-2023
    • Spiriva - Boehringer Ingelheim
      • Table Respiratory Disorders Therapeutics Market
      • Table Figure 12: Respiratory Disorders Therapeutic Market, Global, Annual Revenue for Spiriva ($bn), 2006-2023
    • Xolair - Roche/Novartis
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Xolair, 2017
      • Table Figure 13: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Xolair ($m), 2006-
    • Ventolin - GSK
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Ventolin, 2017
      • Table Figure 14: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Ventolin ($bn), 2006-2023
    • Pulmicort - Astra Zeneca
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Pulmicort, 2017
      • Table Figure 15: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Pulmicort ($bn), 2006-2023
    • Orkambi - Vertex
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Orkambi, 2017
      • Table Figure 16: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Orkambi ($bn), 2015-2023
    • Relvar/Breo Ellipta - GSK
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Relvar/Breo Ellipta, 2017
      • Table Figure 17: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Relvar/Breo Ellipta ($bn), 2013-2023
    • Singulair - Merck & Co.
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Singulair, 2017
      • Table Figure 18: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Singulair ($bn), 2006-2023
    • Esbriet - Roche
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Esbriet, 2017
      • Table Figure 19: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Esbriet ($m), 2008-2023
    • Kalydeco - Vertex
      • Table Respiratory Disorders Therapeutics Market, Global, Approved Indications for Kalydeco, 2017
      • Table Figure 20: Respiratory Disorders Therapeutics Market, Global, Annual Revenue for Kalydeco ($m), 2012-2023
    • Conclusion
  • Pipeline Landscape Assessment
    • Overview
      • Table Figure 21: Respiratory Disorders Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017
    • Pipeline Development Landscape
      • Table Figure 22: Respiratory Disorders Therapeutics Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017
      • Table Figure 23: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Stage of Development, 2017
      • Table Figure 24: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecule Type, 2017
    • Molecular Targets in the Pipeline
      • Table Figure 25: Respiratory Disorders Therapeutics Market, Global, Pipeline by Molecular Targets and Stage of Development, 2017
      • Table Figure 26: Respiratory Disorders Therapeutics Market, Global, Pipeline by Key Indications and Molecular Targets, 2017
    • Clinical Trials
      • Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 27: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017
        • Table Figure 28: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2017
        • Table Figure 29: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2017
        • Table Figure 30: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2017
      • Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 31: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
        • Table Figure 32: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017
        • Table Figure 33: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2017
        • Table Figure 34: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2017
      • Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 35: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development, 2006-2017
        • Table Figure 36: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication, 2006-2017
        • Table Figure 37: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type, 2006-2017
        • Table Figure 38: Respiratory Disorders Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target, 2006-2017
      • Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 39: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development, 2006-2017
        • Table Figure 40: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication, 2006-2017
        • Table Figure 41: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type, 2006-2017
        • Table Figure 42: Respiratory Disorders Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006-2017
    • Assessment of Key Pipeline Products
      • Ivacaftor and Tezacaftor - Vertex
        • Table Figure 43: Respiratory Disorders Therapeutics Market, Global, Revenue for Ivacaftor/Tezacaftor ($bn), 2018-2023
      • (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) - GlaxoSmithKline/Innoviva
        • Table Figure 44: Respiratory Disorders Therapeutics Market, Global, Revenue for (Fluticasone Furoate plus Umeclidinium Bromide plus Vilanterol Trifenatate) ($m), 2017-2023
      • Dupixent - Regeneron Pharmaceuticals/Sanofi
        • Table Figure 45: Respiratory Disorders Therapeutics Market, Global, Revenue for Dupixent ($m), 2017-2023
      • Benralizumab - AstraZeneca/Medimmune
        • Table Figure 46: Respiratory Disorders Therapeutics Market, Global, Revenue for Benralizumab ($m), 2017-2023
      • Tralokinumab - AstraZeneca
        • Table Figure 47: Respiratory Disorders Therapeutics Market, Global, Revenue for Tralokinumab ($m), 2017-2023
      • PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrrolate) - AstraZeneca/Pearl Therapeutics
        • Table Figure 48: Respiratory Disorders Therapeutics Market, Global, Revenue for PT010 ($m), 2017-2023
      • Conclusion
    • Conclusion
  • Multi-scenario Market Forecast to 2023
    • Overall Market Size
      • Table Figure 49: Respiratory Disorders Therapeutics Market, Global, Market Size ($bn), 2016-2023
      • Table Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023
    • Generic Penetration
      • Table Figure 50: Respiratory Disorders Therapeutics Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016-2023
      • Table Respiratory Disorders Therapeutics Market, Global, Usage of Generics Across Key Indications, 2017
    • Revenue Forecast by Molecular Target
      • G Protein-Coupled Receptors
        • Table Figure 51: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for G Protein-Coupled Receptor
      • Immune/Inflammatory Mediators
        • Table Figure 52: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Immune/Inflammatory System Targets ($bn), 2016-2023
      • Transcription Factors
        • Table Figure 53: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Transcription Factor Therapies ($bn), 2016-2023
      • Signal Transduction
        • Table Figure 54: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for Signal Transduction Modulators ($bn), 2016-2023
      • CFTR Modulator
        • Table Figure 55: Respiratory Disorders Therapeutics Market, Global, Annual Revenue Forecast for CFTR Modulators ($bn), 2016-2023
  • Company Analysis and Positioning
    • Table Figure 56: Respiratory Disorders Therapeutics Market, Global, Company Analysis Matrix, 2016-2023
    • Table Figure 57: Respiratory Disorders Therapeutics Market, Global, Cluster Graph by Growth and Market Share, 2016-2023
    • Revenue and Market Share Analysis by Company
      • Table Respiratory Disorders Therapeutics Market, Global, Forecast Revenue by Company, 2016-2023
      • Table Figure 58: Respiratory Disorders Therapeutics Market, Global, Forecast Market Share by Company (%), 2016-2023
      • Table Figure 59: Respiratory Disorders Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
      • Table Figure 60: Respiratory Disorders Therapeutics Market, Global, Revenue by Product Type, 2016-2023
      • GlaxoSmithKline
        • Table Figure 61: Respiratory Disorders Therapeutics Market, Global, GlaxoSmithKline Annual Revenue Forecast ($bn), 2016-2023
      • Vertex
        • Table Figure 62: Respiratory Disorders Therapeutics Market, Global, Vertex Annual Revenue Forecast ($bn), 2016-2023
      • AstraZeneca
        • Table Figure 63: Respiratory Disorders Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2016-2023
      • Roche
        • Table Figure 64: Respiratory Disorders Therapeutics Market, Global, Roche Annual Revenue Forecast ($bn), 2016-2023
      • Boehringer Ingelheim
        • Table Figure 65: Respiratory Disorders Therapeutics Market, Global, Boehringer Ingelheim Annual Revenue Forecast ($bn), 2016-2023
      • Novartis
        • Table Figure 66: Respiratory Disorders Therapeutics Market, Global, Novartis Annual Revenue Forecast ($m), 2016-2023
      • Teva
        • Table Figure 67: Respiratory Disorders Therapeutics Market, Global, Teva Annual Revenue Forecast ($bn), 2016-2023
      • Sumitomo Dainippon
        • Table Figure 68: Respiratory Disorders Therapeutics Market, Global, Sumitomo Dainippon Annual Revenue Forecast ($bn), 2016-2023
      • Regeneron
        • Table Figure 69: Respiratory Disorders Therapeutics Market, Global, Regeneron Annual Revenue Forecast ($bn), 2016-2023
      • Merck & Co.
        • Table Figure 70: Respiratory Disorders Therapeutics Market, Global, Merck & Co. Annual Revenue Forecast ($bn), 2016-2023
    • Company Landscape
      • Table Figure 71: Respiratory Disorders Therapeutics Market, Global, Companies by Type, 2017
    • Marketed and Pipeline Portfolio Analysis
      • Table Figure 72: Respiratory Disorders Therapeutics Market, Global, High-Activity and Late-Stage Developers by Level of Respiratory Specialization, 2017
      • Table Figure 73: Respiratory Disorders Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Respiratory Disorders, 2016-2023
  • Strategic Consolidations
    • Licensing Deals
      • Deal by Region, Year and Value
        • Table Figure 74: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006-2017
        • Table Figure 75: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Indication, 2006-2017
      • Deals by Stage of Development and Value
        • Table Figure 76: Respiratory Disorders Therapeutics Market, Global, Licensing Deal Volume and Value by Stage of Development, 2006-2017
      • Deals by Molecule Type and Molecular Target
        • Table Figure 77: Respiratory Disorders Therapeutics Market, Global, Licensing Deals by Molecule Type and Target, 2006-2017
      • Table for Licensing Deals Valued Above $100m
        • Table Respiratory Disorders Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2017
    • Co-development Deals
      • Deals by Region, Year and Value
        • Table Figure 78: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006-2017
        • Table Figure 79: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Indication, 2006-2017
      • Deals by Stage of Development and Value
        • Table Figure 80: Respiratory Disorders Therapeutics Market, Global, Co-development Deal Volume and Value by Stage of Development, 2006-2017
      • Deals by Molecule Type, Mechanism of Action and Value
        • Table Figure 81: Respiratory Disorders Therapeutics Market, Global, Co-development Deals by Molecule Type and Target, 2006-2017
      • Table for Co-development Deals Valued Above $100m
        • Table Respiratory Disorders Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2017
  • Appendix
    • Bibliography
    • All Pipeline Drugs by Phase
      • Discovery
        • Table Figure 82: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Discovery, 2017
      • Preclinical
        • Table Figure 83: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Preclinical, 2017
      • IND/CTA-Filed/Phase 0
        • Table Figure 84: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, IND/CTA- Filed/Phase 0, 2017
      • Phase I
        • Table Figure 85: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase I, 2017
      • Phase II
        • Table Figure 86: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase II, 2017
      • Phase III
        • Table Figure 87: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Phase III, 2017
      • Pre-registration
        • Table Figure 88: Respiratory Disorders Therapeutics Market, Global, Pipeline Products, Pre-registration, 2017
    • Abbreviations
    • Methodology
      • Coverage
      • Secondary Research
      • Market Size and Revenue Forecasts
      • Pipeline Analysis
      • Competitive Landscape
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report